Biliary Tract Cancer

Updated data from the TOPAZ-1 study revealed improved median overall survival for the full patient population and no new safety signals.
Read More

Final analysis of the phase 2 FIGHT-202 trial demonstrated durable response and a tolerable safety profile for pemigatinib in patients with metastatic cholangiocarcinoma.
Read More

The BilT-04 study revealed that the addition of CPI-613 to gemcitabine/cisplatin was well-tolerated with potential activity in patients with advanced biliary tract cancers.
Read More

Updated FOENIX-CCA2 trial results were found to be consistent with the primary analysis, indicating durable efficacy and continued tolerability of futibatinib in patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements.
Read More

Phase 3 TOPAZ-1 clinical trial established durvalumab plus gemcitabine/cisplatin as a viable first-line standard-of-care treatment regimen for advanced biliary tract cancer.
Read More

Real-world retrospective evidence from Korean patients with advanced biliary tract cancer indicates that efficacy and safety with nab-paclitaxel plus gemcitabine/cisplatin combination were consistent with those previously reported in clinical trials.
Read More

Results of a pilot study demonstrate the feasibility of ctDNA testing and the prognostic value of ctDNA following potentially curative resection in patients with pancreatic/biliary tract malignancies.
Read More

Results of the secondary analysis of the SWOG S0809 trial indicate that nodal status did not impact survival outcomes achieved with adjuvant chemoradiation postresection in patients with extrahepatic CCA or gallbladder cancer.
Read More

The phase 2 NIFE study compared a liposomal irinotecan plus fluorouracil and leucovorin regimen with standard-of-care gemcitabine/cisplatin in patients with advanced biliary tract cancer.
Read More

Results of the NIFTY trial demonstrated that liposomal irinotecan plus 5-fluorouracil and leucovorin significantly improved efficacy outcomes compared with 5-fluorouracil plus leucovorin alone in patients with biliary tract cancer who progressed on prior gemcitabine/cisplatin, with a manageable adverse event profile.
Read More

Page 1 of 4


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: